Deutsche Bank’s Trevi Therapeutics TRVI Stock Holding History
Bought
Maintained
Sold
Other funds holding TRVI
Deutsche Bank's TRVI Position: Q3 2026 in Review
Deutsche Bank reduced its Trevi Therapeutics (TRVI) stake by 6.3% in Q3 2026, selling an estimated $124K and leaving 107,271 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1947.
Deutsche Bank first reported a position in TRVI in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.14M in Q2 2026. 223 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.
- Deutsche Bank held 107,271 shares of Trevi Therapeutics worth $1.54M as of Q3 2026.
- Deutsche Bank sold 7,216 Trevi Therapeutics shares in Q3 2026, an estimated $124K.
- Trevi Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #1947 holding.
- Deutsche Bank first reported a position in Trevi Therapeutics in Q3 2023 and has held it in 12 quarters since.
- Deutsche Bank's Trevi Therapeutics position peaked at $2.14M in Q2 2026.
- 223 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.
Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.